You Have Questions Your Doctor Can't Answer. Genetic Counseling Can Help.

The APOE gene codes for apolipoprotein E, a protein that transports cholesterol and fats throughout your bloodstream and brain. Your brain uses these lipids to build and repair neuronal connections. APOE also influences how your brain clears amyloid beta, a protein that accumulates in Alzheimer’s disease. Everyone carries two copies of APOE, and there are three common variants: E2, E3, and E4. Most people carry E3 (the baseline). The APOE4 variant, carried by roughly 25% of the population, is associated with higher cholesterol levels and accelerated cognitive aging, particularly in the presence of other risk factors like poor sleep, chronic inflammation, or metabolic dysfunction.

The APOE4 variant alters how your body processes dietary cholesterol and how efficiently your brain clears cognitive waste during sleep. People with APOE4 show faster cognitive decline and higher Alzheimer’s risk, particularly if they don’t prioritize sleep quality, manage inflammation, and maintain cardiovascular health. Carrying E4 doesn’t mean you will develop Alzheimer’s; many E4 carriers live cognitively normal lives into old age. But it does mean your brain is more sensitive to lifestyle factors.

If you carry APOE4, you might notice that you’re more sensitive to poor sleep, that brain fog hits harder after inflammatory foods, and that stress accumulates more obviously as cognitive decline. You might also have higher cholesterol levels despite a healthy diet, or notice family members with early cognitive decline. This is genetic, not a character flaw.

BRCA1 codes for a protein that repairs damaged DNA. Every cell in your body constantly experiences DNA damage from radiation, oxidative stress, and normal metabolic processes. BRCA1 finds these errors and fixes them before they become mutations. When BRCA1 is working normally, your cells maintain genomic integrity and your cancer risk stays low. But BRCA1 variants are different from most genes on this page. Most genetic variants reduce protein function by 20-40%. BRCA1 pathogenic variants typically destroy protein function entirely. There are hundreds of known BRCA1 variants, and many carry dramatically higher cancer risk.

A pathogenic BRCA1 variant means your cells cannot repair DNA damage effectively. Women carrying BRCA1 mutations have a 45-87% lifetime risk of breast cancer and a 40-46% risk of ovarian cancer, compared to roughly 12% and 1.3% in the general population. Men carry increased risk of breast cancer, prostate cancer, and pancreatic cancer. The risk isn’t inevitable, but it’s substantial enough that medical management changes significantly.

If you carry a pathogenic BRCA1 variant, you might never feel any symptoms, because the gene doesn’t cause day-to-day health problems. But your cancer risk is real and quantifiable. This is why genetic counseling for BRCA1 is often urgent: it changes screening protocols, may influence decisions about preventive surgery, affects family planning, and informs reproductive carrier screening for your children.

MTHFR codes for an enzyme that converts dietary folate (B9) into methylfolate, the active form your cells use for energy production, DNA synthesis, and neurotransmitter creation. This is not a minor step. Methylfolate is essential for methylation, a fundamental cellular process that regulates gene expression, produces energy (ATP), and builds neurotransmitters like serotonin and dopamine. If folate conversion is impaired, your entire methylation cycle slows down, and downstream effects cascade through your body.

The MTHFR C677T variant, carried by roughly 40% of people with European ancestry, reduces enzyme efficiency by 40-70%. This means your cells are converting B vitamins into usable energy at a fraction of the rate they should be, even if your diet is perfect and your blood folate levels appear normal on standard testing. You can eat organic vegetables, take a multivitamin, and still be functionally depleted at the cellular level because your body cannot process folate properly.

If you have MTHFR C677T or A1298C variants, you might experience unexplained fatigue, brain fog, difficulty concentrating, anxiety, or depression that doesn’t respond to standard treatments. You might have elevated homocysteine (a cardiovascular risk marker) despite good diet and exercise. You might react poorly to certain B vitamins or feel worse when you try to supplement with regular folic acid (the synthetic form). These symptoms make sense when you understand the gene; without that knowledge, they feel random and untreatable.

TCF7L2 codes for a transcription factor that controls how your pancreas secretes insulin in response to rising blood glucose. When TCF7L2 is functioning normally, your pancreas detects glucose rises and releases exactly the right amount of insulin to bring blood sugar back down. This is called glucose homeostasis, and it happens dozens of times per day. TCF7L2 variants don’t cause type 2 diabetes directly, but they make the process less efficient. Instead of a clean, timely insulin response, your pancreas is slightly delayed or slightly underpowered. Over years, this small inefficiency compounds.

The TCF7L2 rs7903146 variant, carried by roughly 30% of the population, increases type 2 diabetes risk by approximately 40-50% relative to people without the variant. People with two copies of the risk allele have roughly 2.5 times higher diabetes risk than non-carriers, even if they maintain normal weight and exercise regularly. This isn’t because they’re eating poorly; it’s because their pancreatic response to glucose is inherently less efficient.

If you carry TCF7L2 variants, you might notice that blood sugar dysregulation runs in your family, or that you struggle to lose weight despite strict dieting and exercise. You might have normal fasting glucose but see your blood sugar spike higher than expected after meals. You might experience afternoon energy crashes or brain fog that resolves with food. These are all signs that your pancreas is working harder than it should. The good news is that lifestyle changes (strength training, lower glycemic diet, adequate sleep) are significantly more effective at preventing diabetes in TCF7L2 carriers than in the general population.

CYP2D6 codes for a liver enzyme that metabolizes roughly 25% of all medications, including antidepressants (SSRIs, tricyclics), antipsychotics, beta-blockers, codeine, and many others. Your CYP2D6 efficiency determines whether a standard medication dose is therapeutic, ineffective, or toxic. The enzyme exists in multiple variants, ranging from complete loss-of-function (ultra-slow metabolizers) to gene duplications (ultra-fast metabolizers). A slow metabolizer might accumulate medication in their bloodstream at dangerous levels, causing severe side effects. A fast metabolizer might metabolize a drug so quickly that it never reaches therapeutic levels.

Roughly 5-10% of the population are poor metabolizers (CYP2D6*5, *6, *7, *8 variants), meaning they have little to no enzyme activity and cannot safely take standard doses of CYP2D6 substrates. Another 10-15% are ultra-rapid metabolizers with gene duplications who need higher doses or different medications. Standard medical practice is to prescribe standard doses. Then, when a patient has side effects or no response, doctors assume the medication doesn’t work or suggest the patient isn’t compliant. But the real problem is genetic.

If you’re a CYP2D6 poor metabolizer, you might have had severe side effects from psychiatric medications that seemed random or like personal failure. You might have tried multiple antidepressants and had intolerable reactions to all of them, when the real issue is that you cannot metabolize them. If you’re ultra-rapid, you might have tried multiple medications with no effect, wondering why nothing works. This is genetic information that changes your entire medication strategy.

The F5 gene codes for factor V, a critical protein in the coagulation cascade. When you cut yourself, a complex series of chemical reactions causes your blood to clot and stop the bleeding. Factor V is one of the proteins that makes this happen. You need enough clotting activity to stop bleeding, but not so much that you form clots in arteries or veins where they shouldn’t be. This balance is tightly regulated. The F5 Leiden variant disrupts this balance by making blood slightly hypercoagulable, meaning it clots more easily than normal.

The F5 Leiden (rs6025, Factor V 1691G>A) variant, carried by roughly 3-5% of people with European ancestry and up to 15% in some Mediterranean populations, increases the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) by approximately 3-8 fold, depending on whether you carry one or two copies of the variant. Risk increases substantially during pregnancy, oral contraceptive use, surgery, or prolonged immobility. Most F5 Leiden carriers never develop a clot; but the risk is real enough that it influences medical decisions.

If you carry the F5 Leiden variant, you might have had an unexplained clot during pregnancy, after surgery, or during a long flight. Or you might have a family history of early clots but no personal history yet. You might be wondering whether oral contraceptives are safe, or whether long flights are risky. These are exactly the questions that genetic counseling answers. Knowing your F5 status changes risk management and helps you make informed decisions about medications and lifestyle.